Opus Genetics (IRD) Net Cash Flow Growth (1y) (2011 - 2026)
Opus Genetics (IRD) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Opus Genetics | 263.72 Mn | 203.72 Mn | - | 29.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.61% |
| Dec 31, 2025 | 326.21% |
| Sep 30, 2025 | 66.21% |
| Jun 30, 2025 | -62.78% |
| Mar 31, 2025 | 443.44% |
| Dec 31, 2024 | -177.43% |
| Sep 30, 2024 | -301.31% |
| Jun 30, 2024 | -681.60% |
| Mar 31, 2024 | 8.39% |
| Dec 31, 2023 | -71.68% |
| Sep 30, 2023 | 174.86% |
| Jun 30, 2023 | 144.53% |
| Mar 31, 2023 | 31.05% |
| Dec 31, 2022 | 1,160.03% |
| Sep 30, 2022 | -59.78% |
| Jun 30, 2022 | -116.29% |
| Mar 31, 2022 | 8.86% |
| Dec 31, 2021 | -85.43% |
| Sep 30, 2021 | -1,403.03% |
| Jun 30, 2021 | 3,517.79% |